HURA (TuHURA Biosciences) Other Long-Term Liabilities: $-0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HURA TuHURA Biosciences Inc HURA
11 GF Score
Price $2.22
View Full Analysis

What is TuHURA Biosciences Other Long-Term Liabilities?

TuHURA Biosciences HURA -2.42% 11 Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2026. GuruFocus rates HURA with a GF Score™ of 11/100.

TuHURA Biosciences's other long-term liabilities for the quarter that ended in Jun. 2026 was $-0.00 Mil.

TuHURA Biosciences's quarterly other long-term liabilities declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($-0.00 Mil) but then stayed the same from Mar. 2026 ($-0.00 Mil) to Jun. 2026 ($-0.00 Mil).

TuHURA Biosciences's annual other long-term liabilities declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

TuHURA Biosciences Other Long-Term Liabilities Related Terms

TuHURA Biosciences Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for TuHURA Biosciences's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences Other Long-Term Liabilities Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
0.00 -0.00 0.00 0.00 0.00

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.09 0.00 -0.00 -0.00
HURA
11GF Score
TuHURA Biosciences Inc HURA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TuHURA Biosciences Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $-0.00 Mil mean?
TuHURA Biosciences (HURA) has a Other Long-Term Liabilities of $-0.00 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on TuHURA Biosciences and its competitors.
Is TuHURA Biosciences' Other Long-Term Liabilities too high?
TuHURA Biosciences' current Other Long-Term Liabilities is $-0.00 Mil. Overall, TuHURA Biosciences has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does TuHURA Biosciences' Other Long-Term Liabilities compare to CNTB and CUE?
TuHURA Biosciences' Other Long-Term Liabilities of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on TuHURA Biosciences and its competitors. TuHURA Biosciences's current Other Long-Term Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TuHURA Biosciences stock overvalued right now?
TuHURA Biosciences (HURA) has a current Other Long-Term Liabilities of $-0.00 Mil. The current Other Long-Term Liabilities is $-0.00 Mil. TuHURA Biosciences' overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For TuHURA Biosciences (HURA), the current Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TuHURA Biosciences Business Description

Other Exchanges PL3:Germany
Address 10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
11GF Score

Get the complete analysis for HURA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.22
Price